

**31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona**

Prostate and Urologic Cancers Collaborative Group Meeting

**Wednesday, March 8, 2017
8:00 a.m. – 12:00 p.m.**

Augustine Room

Chair:

Martin Sanda, M.D., Emory University

Co-chair:

John Semmes, Ph.D., Eastern Virginia Medical School

NCI Program Directors:

- Jacob Kagan, Ph.D., M.Sc., National Cancer Institute
- Richard Mazurchuk, Ph.D., National Cancer Institute

Agenda

8:00 a.m. – 8:10 a.m. Charge to Collaborative Groups

Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

8:10 a.m. – 8:20 a.m.

Welcome:

- Martin Sanda, M.D., Emory University
- John Semmes, Ph.D., Eastern Virginia Medical School
- Jacob Kagan, Ph.D., M.Sc., National Cancer Institute
- Richard Mazurchuk, Ph.D., National Cancer Institute

8:20 a.m.- 8:30 a.m.

Report from Patient Advocates

Merel Nissenberg, J.D., NASPCC/Mountain Foundation for Lung Cancer

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Prostate and Urologic Cancers Collaborative Group Meeting

8:30 a.m. –10:00 a.m.

Review of Ongoing Team Projects Including Pre-Validation Studies and Studies Funded by Set-aside Funds

Short 10 minute presentations and discussion by all teams. Discuss successes and failures; is/are there better way/s to achieve the goals? What lessons were learned from less successful projects: scientific, management and leadership.

Presenters:

- Verification of Urinary Glycoprotein Biomarkers Associated with Aggressive Prostate Cancer
Hui Zhang, Ph.D., M.S., Johns Hopkins University
- Development of Protein Biomarkers in Post-DRE Urine for Use in Liquid Biopsy of Prostate Cancer
Julius O. Nyalwidhe, Ph.D., Eastern Virginia Medical School
- Evaluation of Transcriptomic Biomarkers of Aggressive Prostate Cancer in CPDR Cohort
Arul M. Chinnaiyan, M.D., Ph.D., University of Michigan
- CPDR (DoD) and EDRN (NCI) Inter Agency Agreement (IAA) - GU Group Collaborations
Gyorgy Petrovics, Ph.D., Center for Prostate Disease Research
- Proteomic Evaluation of Candidate Biomarkers from Genomic Studies for Discriminating Indolent from Aggressive Prostate Cancer
Tao Liu, Ph.D., Pacific Northwest National Laboratory
- Martin Sanda, M.D., Emory University

Discussion

10:00 a.m. – 12:00 p.m.

Core Fund Projects

10:00 a.m. – 10:30 a.m.

Review and Discussion of the Draft Proposal for Fusion Imaging Pre-validation Study
John Wei, M.D., M.S., University of Michigan

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Prostate and Urologic Cancers Collaborative Group Meeting

Core Fund Projects Continued

- 10:30 a.m. – 11:00 a.m.* Review Progress and Discussion on Longitudinal Testing of Validated Biomarkers
○ Dan Chan, Ph.D., Johns Hopkins University
○ John Wei, M.D., M.S., University of Michigan
- 11:00 a.m. – 11:30 p.m.* Review Progress and Discussion of the Expansion of the Tissue Upgrading Study
Martin Sanda, M.D., Emory University
- 11:30 a.m. – 12:00 p.m.* Discussion of the *in situ* Verification of lncRNA Markers
○ Scott Tomlins, Ph.D., University of Michigan
○ Robin Leach, Ph.D., The University of Texas Health Sciences Center, San Antonio
○ Shiv Srivastava, Ph.D., Center for Prostate Disease Research

12:00 p.m. **Adjourn**